|
1
|
Rice TW, Rusch VW, Apperson-Hansen C,
Allen MS, Chen LQ, Hunter JG, Kesler KA, Law S, Lerut TE, Reed CE,
et al: Worldwide esophageal cancer collaboration. Dis Esophagus.
22:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li LY, Li EM, Wu ZY, Cao HH, Shen JH, Xu
XE, Chen B, Wu JY and Xu LY: Overexpression of GRB2 is correlated
with lymph node metastasis and poor prognosis in esophageal
squamous cell carcinoma. Int J Clin Exp Pathol. 7:3132–3140.
2014.PubMed/NCBI
|
|
3
|
Wang Y, Sheng S, Zhang J, Dzinic S, Li S,
Fang F, Wu N, Zheng Q and Yang Y: Elevated maspin expression is
associated with better overall survival in esophageal squamous cell
carcinoma (ESCC). PLoS One. 8:e635812013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thijssen VL, Heusschen R, Caers J and
Griffioen AW: Galectin expression in cancer diagnosis and
prognosis: A systematic review. Biochim Biophys Acta. 1855:235–247.
2015.PubMed/NCBI
|
|
5
|
Fortuna-Costa A, Gomes AM, Kozlowski EO,
Stelling MP and Pavao MS: Extracellular galectin-3 in tumor
progression and metastasis. Front Oncol. 4:1382014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Braeuer RR, Shoshan E, Kamiya T and
Bar-Eli M: The sweet and bitter sides of galectins in melanoma
progression. Pigment Cell Melanoma Res. 25:592–601. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Inohara H, Honjo Y, Yoshii T, Akahani S,
Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A and Kubo T:
Expression of galectin-3 in fine-needle aspirates as a diagnostic
marker differentiating benign from malignant thyroid neoplasms.
Cancer. 85:2475–2484. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sakaki M, Fukumori T, Fukawa T, Elsamman
E, Shiirevnyamba A, Nakatsuji H and Kanayama HO: Clinical
significance of Galectin-3 in clear cell renal cell carcinoma. J
Med Invest. 57:152–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang N, Song X, Xie J, Xu D, Liu F, Yu X,
Tian Y, Liu Z, Qiao L and Zhang J: Effect of galectin-3 on the
behavior of Eca-109 human esophageal cancer cells. Mol Med Rep.
11:896–902. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qiao L, Liang N, Xie J, Luo H and Zhang J,
Deng G, Li Y and Zhang J: Gene silencing of galectin-3 changes the
biological behavior of Eca109 human esophageal cancer cells. Mol
Med Rep. 13:160–166. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hess AR, Margaryan NV, Seftor EA and
Hendrix MJ: Deciphering the signaling events that promote melanoma
tumor cell vasculogenic mimicry and their link to embryonic
vasculogenesis: Role of the Eph receptors. Dev Dyn. 236:3283–3296.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao Z, Bao M, Miele L, Sarkar FH, Wang Z
and Zhou Q: Tumour vasculogenic mimicry is associated with poor
prognosis of human cancer patients: A systemic review and
meta-analysis. Eur J Cancer. 49:3914–3923. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mourad-Zeidan AA, Melnikova VO, Wang H,
Raz A and Bar-Eli M: Expression profiling of Galectin-3-depleted
melanoma cells reveals its major role in melanoma cell plasticity
and vasculogenic mimicry. Am J Pathol. 173:1839–1852. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qiao L, Liang N, Zhang J, Xie J, Liu F, Xu
D, Yu X and Tian Y: Advanced research on vasculogenic mimicry in
cancer. J Cell Mol Med. 19:315–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lotan R, Ito H, Yasui W, Yokozaki H, Lotan
D and Tahara E: Expression of a 31-kDa lactoside-binding lectin in
normal human gastric mucosa and in primary and metastatic gastric
carcinomas. Int J Cancer. 56:474–480. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schoeppner HL, Raz A, Ho SB and Bresalier
RS: Expression of an endogenous galactose-binding lectin correlates
with neoplastic progression in the colon. Cancer. 75:2818–2826.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Canesin G, Gonzalez-Peramato P, Palou J,
Urrutia M, Cordón-Cardo C and Sánchez-Carbayo M: Galectin-3
expression is associated with bladder cancer progression and
clinical outcome. Tumour Biol. 31:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Knapp JS, Lokeshwar SD, Vogel U,
Hennenlotter J, Schwentner C, Kramer MW, Stenzl A and Merseburger
AS: Galectin-3 expression in prostate cancer and benign prostate
tissues: Correlation with biochemical recurrence. World J Urol.
31:351–358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Honjo Y, Nangia-Makker P, Inohara H and
Raz A: Down-regulation of galectin-3 suppresses tumorigenicity of
human breast carcinoma cells. Clin Cancer Res. 7:661–668.
2001.PubMed/NCBI
|
|
21
|
Newlaczyl AU and Yu LG: Galectin-3-a
jack-of-all-trades in cancer. Cancer Lett. 313:123–128. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rodriguez MI, Peralta-Leal A, O'Valle F,
Rodriguez-Vargas JM, Gonzalez-Flores A, Majuelos-Melguizo J, López
L, Serrano S, de Herreros AG, Rodríguez-Manzaneque JC, et al:
PARP-1 regulates metastatic melanoma through modulation of
vimentin-induced malignant transformation. PLoS Genet.
9:e10035312013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang NN, Zhu H, Zhang HJ, Zhang WF, Jin
HL, Wang L, Wang P, He GJ, Hao B and Shi RH: HIF-1α induces
VE-cadherin expression and modulates vasculogenic mimicry in
esophageal carcinoma cells. World J Gastroenterol. 20:17894–18904.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hess AR, Seftor EA, Gruman LM, Kinch MS,
Seftor RE and Hendrix MJ: VE-cadherin regulates EphA2 in aggressive
melanoma cells through a novel signaling pathway: Implications for
vasculogenic mimicry. Cancer Biol Ther. 5:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
